This is the authors' abstract. We don't add key points for this paper.
This review aims to determine the role of S-adenosylmethionine (SAMe) supplementation as an alternative therapeutic option, particularly for individuals with inadequate responses to conventional antidepressive treatments. The effects of SAMe on depression are analysed through its role in modulating neurotransmitter metabolism, reducing neuroinflammation, enhancing neuroplasticity, and regulating gene expression. These mechanisms may contribute to the efficacy of SAMe in treating depression, particularly in treatment-resistant cases. The review also addresses SAMe's potential use in managing other psychiatric disorders and neurological diseases.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Labhade et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: